LCZ696 was superior to enalapril in reducing the risks of death and hospitalization for heart failure in patients with heart failure.
Does LCZ696 reduce the risks of death and hospitalization for heart failure compared to enalapril in patients with heart failure?
Patients with heart failure
LCZ696 (Angiotensin-Neprilysin Inhibition)
Enalapril
Death and hospitalization for heart failurehard clinical
LCZ696 (angiotensin-neprilysin inhibition) is superior to enalapril in reducing death and heart failure hospitalization in patients with heart failure.
LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Building similarity graph...
Analyzing shared references across papers
Loading...
John J.V. McMurray
Milton Packer
Akshay S. Desai
New England Journal of Medicine
Brigham and Women's Hospital
Imperial College London
The University of Texas Southwestern Medical Center
Building similarity graph...
Analyzing shared references across papers
Loading...
McMurray et al. (Sat,) reported a other. LCZ696 was superior to enalapril in reducing the risks of death and hospitalization for heart failure in patients with heart failure.
www.synapsesocial.com/papers/697a3929e3885199a727c623 — DOI: https://doi.org/10.1056/nejmoa1409077